Literature DB >> 22646508

Pathological complete response and accelerated drug approval in early breast cancer.

Tatiana M Prowell1, Richard Pazdur.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22646508     DOI： 10.1056/NEJMp1205737

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  118 in total

Review 1.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

Review 2.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Tari A King; Monica Morrow
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

3.  Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Authors:  Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; Qing Liu; André Robidoux; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Soonmyung Paik; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316

Review 4.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

Review 5.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Authors:  Carlos L Arteaga; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

Review 6.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

7.  Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.

Authors:  Marieke E M van der Noordaa; Ileana Ioan; Emiel J Rutgers; Erik van Werkhoven; Claudette E Loo; Rosie Voorthuis; Jelle Wesseling; Japke van Urk; Terry Wiersma; Vincent Dezentje; Marie-Jeanne T F D Vrancken Peeters; Frederieke H van Duijnhoven
Journal:  Ann Surg Oncol       Date:  2021-05-12       Impact factor: 5.344

Review 8.  Benefit and harms of new anti-cancer drugs.

Authors:  Francisco E Vera-Badillo; Mustafa Al-Mubarak; Arnoud J Templeton; Eitan Amir
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

Review 9.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

10.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Authors:  William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.